Evaluating the impact of vosoritide on complications of achondroplasia.
Vosoritide may not worsen complications in children with achondroplasia and might reduce their frequency, but further research is needed to confirm these findings.
Where it sits
this study against the rest of the vosoritide corpusSummary and findings
This study analyzed the impact of vosoritide on complications in children with achondroplasia across six clinical trials. A total of 230 participants received doses ranging from 2.5 to 30 μg/kg/day. The findings indicated that the incidence of various complications was generally lower than natural history rates.
Abstract
<h4>Purpose</h4>Impaired endochondral bone growth in people with achondroplasia causes complications that impair function, cause pain, require surgery, and contribute to mortality. Rates of complications in participants with achondroplasia enrolled in clinical trials of vosoritide, a targeted treatment, were analyzed and compared with published natural history (NH) rates.<h4>Methods</h4>Prevalence (medical history + new events post-treatment initiation) and incidence (new/worsening events posttreatment initiation) were calculated for complications across 6 clinical trials (2.5-30 μg/kg/day vosoritide) in children with achondroplasia, stratified by age at treatment initiation (<5 years/≥5 years). Complication-related procedures and mortality rates were examined.<h4>Results</h4>By August 2024, 230 participants received vosoritide (68 aged <5 years at treatment initiation [exposure, 289.1 person-years]; 162 aged ≥5 years at treatment initiation [exposure, 834.5 person-years]). Prevalence for most complications was consistent with or lower than NH rates. Incidence of leg malalignment; foramen magnum stenosis; spinal stenosis; kyphosis; lordosis; hydrocephalus; ear, nose, and throat complications; and pain was generally lower than NH rates. Foramen magnum decompression frequency was 3.0% overall (5.9% in participants who initiated treatment aged <2 years). Crude mortality was lower than NH rates.<h4>Conclusion</h4>Vosoritide was not associated with worsening of complications in children with achondroplasia and may reduce their frequency.
Background
This paper addresses the complications arising from impaired endochondral bone growth in children with achondroplasia, a condition that can lead to significant functional impairments and increased mortality. Prior studies have documented the natural history rates of these complications, but the impact of vosoritide, a targeted treatment, on these rates had not been comprehensively evaluated. Understanding the effects of vosoritide is crucial for assessing its potential benefits and risks in this population.
Methods
The study analyzed data from six clinical trials involving children with achondroplasia who received vosoritide at doses ranging from 2.5 to 30 μg/kg/day. The population included 230 participants, with stratification by age at treatment initiation (<5 years and ≥5 years). The primary outcomes measured were the prevalence and incidence of complications, as well as complication-related procedures and mortality rates.
Results
The prevalence of most complications was consistent with or lower than natural history rates. The incidence of leg malalignment, foramen magnum stenosis, spinal stenosis, kyphosis, lordosis, hydrocephalus, ear, nose, and throat complications, and pain was generally lower than natural history rates. The frequency of foramen magnum decompression was reported at 3.0% overall.
Interpretation
The findings suggest that vosoritide may not worsen complications in children with achondroplasia and could potentially reduce their frequency. However, the effect sizes observed may not be clinically significant, and the reliance on clinical trial data introduces confounding factors that limit generalizability. Further studies are needed to confirm these findings in broader populations and longer follow-up periods.
Key findings
- 230 participants received vosoritide, with 68 aged <5 years and 162 aged ≥5 years.
- Foramen magnum decompression frequency was 3.0% overall and 5.9% in participants who initiated treatment aged <2 years.
- Crude mortality was lower than natural history rates.
Limitations
- Data derived from clinical trials may not represent the general population.
- Follow-up duration and specific methodologies for assessing complications were not detailed.